Testing a shorter medication course for latent tuberculosis infection

This trial is testing whether rifapentine, a medication taken daily for just 6 weeks, works as well as the standard treatments that take 12–16 weeks to complete. The study enrolls people who have latent tuberculosis infection (meaning they carry the bacteria but don't have active disease) and are at higher risk of it developing into active tuberculosis. Researchers will compare how safe the medication is and how well it prevents active tuberculosis from developing.

Current treatments for latent tuberculosis require 12–16 weeks of medication, which is a long commitment that many people don't finish. This trial tests whether a much shorter 6-week course of this medication could be just as effective, making it easier for people to complete treatment and prevent tuberculosis from becoming active.